Recommendations on the use of azole antifungals in hematology-oncology patients
Revista Española de Quimioterapia · 19.05.2023 · 36 (3) · 236-258
DOI: 10.37201/req/013.2023 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Revista Española de Quimioterapia, online erschienen am 05.04.2023. Verfasst von J R Azanza und 20 weiteren Autor:innen. Beteiligte Einrichtung: José Ramón Azanza,Servicio de Farmacología Clínica. Clínica Universitaria de Navarra. Pamplona. Spain. jrazanza@unav.es. Hauptthemen laut MEDLINE: Antineoplastic Agents, Hematologic Neoplasms. Die Arbeit wurde bisher 47-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The administration of antifungals for therapeutic and, especially, prophylactic purposes is virtually a constant in patients requiring hematology-oncology treatment. Any attempt to prevent or treat Aspergillus or Mucor infections requires the administration of some drugs in the azole group, which include voriconazole, posaconazole and isavuconazole, noted for their activity against these pathogens. One very relevant aspect is the potential risk of interaction when associated with one of the antineoplastic drugs used to treat hematologic tumors, with serious complications. In this regard, acalabrutinib, bortezomib, bosutinib, carfilzomib, cyclophosphamide, cyclosporine A, dasatinib, duvelisib, gilteritinib, glasdegib, ibrutinib, imatinib, nilotinib, ponatinib, prednisone, ruxolitinib, tacrolimus, all-transretinoic acid, arsenic trioxide, venetoclax, or any of the vinca alkaloids, are very clear examples of risk, in some cases because their clearance is reduced and in others because of increased risk of QTc prolongation, which is particularly evident when the drug of choice is voriconazole or posaconazole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- José Ramón Azanza,Servicio de Farmacología Clínica. Clínica Universitaria de Navarra. Pamplona. Spain. jrazanza@unav.es.
Zitieren
APA
Azanza, J. R., Mensa, J., Barberán, J., Vázquez, L., Pérez de Oteyza, J., Kwon, M., Yáñez, L., Aguado, J. M., Cubillo Gracian, A., Solano, C., Ruiz Camps, I., Fortún, J., Salavert Lletí, M., Gudiol, C., Olave Rubio, T., Solano, C., García-Vidal, C., Rovira Tarrats, M., Suárez-Lledó Grande, M., …, & Dueñas Gutiérrez, C. (2023). Recommendations on the use of azole antifungals in hematology-oncology patients. Revista Española de Quimioterapia, 36(3), 236-258. https://doi.org/10.37201/req/013.2023
Vancouver
Azanza JR, Mensa J, Barberán J, Vázquez L, Pérez de Oteyza J, Kwon M, et al. Recommendations on the use of azole antifungals in hematology-oncology patients. Revista Española de Quimioterapia. 2023;36(3):236-258. doi:10.37201/req/013.2023
BibTeX
@article{Azanza2023,
author = {Azanza, J R and Mensa, J and Barberán, J and Vázquez, L and Pérez de Oteyza, J and Kwon, M and Yáñez, L and Aguado, J M and Cubillo Gracian, A and Solano, C and Ruiz Camps, I and Fortún, J and Salavert Lletí, M and Gudiol, C and Olave Rubio, T and Solano, C and García-Vidal, C and Rovira Tarrats, M and Suárez-Lledó Grande, M and González-Sierra, P and Dueñas Gutiérrez, C},
title = {Recommendations on the use of azole antifungals in hematology-oncology patients},
journal = {Revista Española de Quimioterapia},
year = {2023},
volume = {36},
number = {3},
pages = {236--258},
doi = {10.37201/req/013.2023}
}
EUVIMED